Vanda grabs Lilly molecule in $100M deal; GW Pharma earns milestone;

@FierceBiotech: Video games unravel drug discovery riddles. Story | Follow @FierceBiotech

@JohnCFierce: ALS patients taking D-I-Y version of experimental Neuraltus drug--sheer desperation. Via WSJ: Article. | Follow @JohnCFierce

@RyanMFierce: Takeda is backing genomic and computer analysis of psychiatric disease with Sage Bionetworks, others. News | Follow @RyanMFierce

> Vanda Pharmaceuticals ($VNDA) has nabbed the rights to one of Eli Lilly's ($LLY) small molecules for $1 million down and $99 million in milestones. The NK-1R antagonist--VLY-686VLY-686, formerly known at Lilly as LY686017--has achieved some proof-of-concept data for treating alcohol dependence. Release

> GW Pharma reports that it has earned a €11.9 million milestone as the result of an amendment to its license deal with Almirall. Release

> The U.K.'s Conformetrix has inked a research collaboration pact with AstraZeneca ($AZN), with plans to apply its NMR-based technology across AstraZeneca's pre-clinical therapeutic pipeline. Release

Pharma News

@FiercePharma: After winning huge fines against J&J, Arkansas officials say they're not counting the money yet. Wise move. More | Follow @FiercePharma

> French market toughens up on drug prices, safety. Article

> GSK, sales rep lawyers argue OT case at Supreme Court. Item

Medical Devices News

 @FierceMedDev: Genetic testing for drug intolerance. Item | Follow @FierceMedDev

> Australia, New Zealand, recall J&J hip implant components. News

> Siemens' Sorensen: Diagnostics save beaucoup bucks. Story

> CyVek nails down $3M for diagnostics test system. Article

> GE Healthcare, Japanese partner to pursue Alzheimer's Dx. More

Biotech IT News

> Pharma groups stand out in social media realm. Item

> Google VC doubles down on Big Data after biotech bets. Piece

> Amazon hungers for genomics data after NIH pact. More

> Wellcome joins chorus calling for free online access to medical research. Article

And Finally… The American Society of Plastic Surgeons says that "chin augmentation" is the fastest growing procedure in the plastic surgery field. They say the trend has been spurred, in part, by the increasing popularity of video chats. Release

 

Suggested Articles

After the loss of its longtime CEO at the start of the year, a morphing MorphoSys is now losing its CSO.

A new study shows how circular ecDNA outside of the chromosome in cancer cells drives oncogenes, making tumors more aggressive.

The U.K. is currently a leading European location for clinical trials but that position could be threatened by Brexit and other factors.